Imfinzi® (durvalumab) – New orphan indication
September 5, 2022 - AstraZeneca announced the FDA approval of Imfinzi (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
Download PDF
